3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
3
NETWORK
2
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Conditions
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Hepatocellular
3
Small Cell Lung Carcinoma
2
Lung Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Trauma, Nervous System
1
Thoracic Injuries
1
Stomach Neoplasms
1
Skin Neoplasms
1
Rectal Neoplasms
1
Radiculopathy
1
Pneumonia
1
Pathologic Complete Response
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Laryngeal Neoplasms
1
Klippel-Feil Syndrome
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
11
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
Observation
×
Clear all
NCT06887348
2026-01-12
RPx
Replimune, Inc.
Recruiting
50 enrolled